Introduction: Intravesical bacillus Calmette-Guérin therapy is the gold standard adjuvant treatment for patients with high grade nonmuscle invasive bladder cancer. Despite the association between the metabolic syndrome and bladder cancer, the association between the metabolic syndrome and bacillus Calmette-Guérin failure is unknown. In this study we characterize disease recurrence following bacillus Calmette-Guérin in patients with and without metabolic syndrome.
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Abbreviations and Acronyms

BCG = bacillus
Key Words: BCG vaccine, metabolic syndrome, urinary bladder neoplasms, outcome assessment, recurrence Bladder cancer is the second most commonly diagnosed malignancy of the genitourinary system, with an estimated 77,000 new cases diagnosed in 2016, of which 70% are nonmuscle invasive.
1,2 The prognosis of this form of the disease is generally excellent. 3 This is due in part to the use of intravesical bacillus Calmette-Guérin, which has been shown to be effective in eradicating carcinoma in situ, as well as in preventing disease recurrence and progression following surgical resection of papillary tumors. Regrettably, BCG fails in up to 40% of patients. 2 The etiology of BCG failure is not well understood and is the subject of continual investigation, as the ability to identify patients in whom BCG will fail would allow for pursuit of an alternative treatment approach. This could minimize potential risks associated with BCG use, prevent delays in the use of more effective alternative treatments and help preserve BCG for those who are likely to benefit, which is particularly important in the setting of worldwide BCG shortages. 4, 5 Recent investigations have demonstrated an association between metabolic syndrome and an increased risk of bladder cancer. 6 MetS is an increasingly prevalent, complex disorder characterized by the co-occurrence of several factors, namely insulin resistance as in diabetes mellitus, hyperlipidemia, hypertension and visceral obesity. 
Materials and Methods
Patient Cohort
Patients undergoing endoscopic resection of bladder tumors at our institution between March 2012 and July 2015 were identified from the medical record by CPT-4 codes for transurethral biopsy and resection (52204, 52214, 52224, 52234, 52235, 52240). Pathological and clinical reports were reviewed, and patients with NMIBC who were treated with intravesical BCG therapy were selected for inclusion. Generally BCG was given per the SWOG protocol as an induction course of 6-weekly instillations followed by maintenance of 3-weekly instillations at 3 and 6 months following induction, and then every 6 months for up to 3 years. 16 We excluded all patients with nonurothelial variant histology. We also excluded patients with a diagnosis of upper tract urothelial carcinoma within 1 year, metastatic disease, less than 3 months of followup or those who underwent cystectomy within 3 months of diagnosis for reasons other than recurrence or progression. Followup was calculated from the time of the last cystoscopy. Study conduct was approved by the institutional review board.
Independent Variables
Metabolic syndrome was defined as the presence of 3 or more of the 4 conditions of DM, HTN, HLD or a BMI 30 kg/m 2 or greater. DM, HTN and HLD were identified as 1) an ICD-9 diagnosis in the medical record, or 2) documentation of prescribed medications used to treat these conditions. The BMI cutoff was defined a priori and according to the WHO and National Institutes of Health classification of obesity (BMI 30 kg/m 2 or greater). This was also selected to maintain consistency with other studies of MetS and the role of obesity in bladder cancer. 17 
Dependent Variables
Our dependent variable of interest was recurrence or progression of disease. Recurrence was defined as the presence of urothelial carcinoma on biopsy or repeat resection.
Patients with a lesion visible on cystoscopy that warranted intervention in the office (eg fulguration) were also classified as having disease recurrence. Progression was any increase in disease grade or stage. Cases of recurrence or progression were classified as BCG failures, and categorized into the groups of refractory (presence of disease after induction but within 6 months of diagnosis), relapsing (recurrence of disease after 6 months) or intolerant (cessation or reduction in dose secondary to symptoms). Patients with persistent suspicious cytology but negative cystoscopy were evaluated at the discretion of the surgeon, generally with bladder biopsies and upper tract imaging. These cases were not considered failures unless a biopsy detected recurrence or a lesion warranted intervention, as previously mentioned.
Statistical Analysis
Comparisons between categorical variables were tested using chi-squared analysis and Fisher's exact test. Twosample Student's t-test was used to test for differences between continuous variables. Differences in disease-free survival were analyzed using the Kaplan-Meier method.
Cox proportional hazards models were used to estimate hazard ratios for covariates of interest and DFS. Cox-Snell residuals were calculated to evaluate the fit of the final model. The hazard function has an approximate exponential distribution and provides evidence that the model fits the data well. All statistical analyses were performed with STATAÒ statistical software version 14.
Results
A total of 90 patients underwent transurethral bladder tumor resection for NMIBC during the study period, received adjuvant BCG therapy and met all inclusion criteria for analysis. Our cohort was predominantly male (80.0%) with a mean age of 69. A total of 48 patients were treated with induction BCG only and 31 patients received BCG induction and maintenance. One patient underwent induction and maintenance with 1/3 dose BCG secondary to BCG shortage. Six patients underwent induction with BCG plus interferon. Only 4 patients underwent incomplete induction due to BCG shortages (2), secondary to intolerable side effects (1) and preference to stop treatments (1) . Of the 37 cases that BCG failure (defined as recurrence, progression or intolerance of therapy) 19 were refractory, 16 were relapsing and only 2 were intolerant. Associations between the type of BCG failure and presence of MetS were not significant.
Lastly, we created a multivariable model incorporating variables significant on univariate analysis and our variable of interest, MetS. In this model MetS was not significant when accounting for other variables (HR 1.53, 95% CI 0.71e3.29, p¼0.28). However, given the association between BMI and HTN and recurrence or progression on 
Discussion
There is no current standard therapy for patients in whom BCG therapy fails. Current recommendations include additional intravesical treatments, extirpative surgery, bladder sparing protocols (maximal resection and chemoradiation) or clinical trials. The optimal treatment pathways have been heavily debated. 18 However, there continues to be extensive divergence in the aggressive treatment of patients with bladder cancer. 19 Therefore, determining clinically useful predictors of response to BCG may help aid decisions on definitive treatment and set appropriate expectations. Our hypothesis that MetS is associated with BCG efficacy was predicated on several large studies suggesting an association between MetS and bladder cancer pathogenesis. In a prospective cohort of 580,000 patients Häggström et al demonstrated that MetS was significantly associated with an increased risk of bladder cancer in men. 20 A meta-analysis by Esposito et al confirmed that men with MetS were significantly more likely to be diagnosed with bladder cancer. 6 Although the mechanisms that link MetS and cancer risk are not fully understood, it is well established that MetS induces a chronic, low grade inflammatory state with changes found in immune and nonimmune cells. 12 MetS decreases cellular immunity by limiting chemotaxis, Figure.
Kaplan-Meier survival curve stratified by presence of MetS greater) was associated with an increased risk of disease recurrence, disease progression and cancer specific mortality in a cohort study of 892 patients after adjusting for other factors. 17 Similarly, a study of 726 patients with NMIBC reported that high BMI values at diagnosis were associated with an increased risk of recurrence. 22 The growing body of literature suggesting the negative influence of obesity on genitourinary malignancies and oncologic outcomes has led to speculation regarding the underlying biological mechanisms. One proposed pathogenesis involves excess adipocytes, particularly in visceral adipose tissue, resulting in an overproduction of pro-inflammatory cytokines and macrophage recruitment contributing to a protumorigenic environment. 23 Other models also suggest polymorphisms of adiponectin and its receptor genes. 24 Further studies are required to better elucidate this relationship, and mechanistic targets for disrupting the obesity-cancer association could be exploited for therapeutic intervention. Finally, we did not find an association between MetS and the type of BCG failure. This was likely secondary to the small sample size of patients in whom BCG failed in the study period. Larger sample sizes are required to investigate this matter further. Our findings should be considered in the context of their limitations. This study was performed retrospectively and we were limited by the data available in medical records. While we collected and reported data on BCG failure types, these definitions are inconsistently defined in the literature and may not represent unique clinical states. 2 Additionally, our patient cohort was managed with a variety of surveillance protocols and an institutional pathway could have enhanced the consistency of followup and the identification of failures. MetS was defined simply as present or absent and no degree of severity was used in our analysis (eg HgbA1c or serum cholesterol levels), with the exception of BMI. Finally, BMI has been replaced by abdominal circumference in the definition of MetS, a change that underscores the importance of visceral adiposity in the pathophysiology. 25 Unfortunately, abdominal circumference could not be obtained from the medical records in this retrospective study. Several studies cited here have also used BMI in the definition of MetS as a substitute for abdominal circumference, as this is not generally obtained during routine office visits. 17, 20, 22 Despite these limitations, our study addresses a concern that may become more important as patients with NMIBC become older with more comorbidities (including MetS), and as BCG continues to be in short supply outside clinical trials, and requires sparing and rationed use. There are several practical applications for these data. This study better informs the urologist managing high risk NMIBC with BCG regarding the potentially decreased responsiveness of patients with an elevated BMI to BCG treatments. In addition, similar to the smoking cessation counseling opportunities that come with a bladder cancer diagnosis, the treatment of patients with BCG who have an elevated BMI can be an opportunity to counsel patients to engage in healthy lifestyle choices that could potentially reduce the chances of BCG failure and certainly improve cardiovascular health. 26 Patients with decreased immune responsiveness to BCG, potentially those with multiple risk factors including elevated BMI, may be better served with intravesical cytotoxic agents (eg gemcitabine or mitomycin C) in lieu of a second induction course of BCG. Clinical studies could be planned to evaluate this hypothesis. This issue is especially important in the era of upcoming global BCG shortage. 4 Moreover, these results address a concept in the expanding field of immunotherapy for urothelial carcinoma, specifically regarding the effect of host immune status on the efficacy of immunotherapy. Recently approved novel immunomodulators, such as anti-programmed cell death ligand-1, rely heavily on the function of the host's immune system. Further research is needed to determine whether these therapies are similarly effective in patients unable to mount a vigorous immune response. Finally, our results highlight the need for predictive models to help identify patients in whom BCG therapy will fail and, therefore, warrant more aggressive treatment up front.
